Kailera Therapeutics has completed enrollment of roughly 4,900 participants across three Phase 3 trials of ribupatide, a once-weekly injection activating both GLP-1 and GIP receptors, with topline data expected mid-2028. One trial includes an open-label semaglutide 2.4 mg comparator arm in adults with a BMI of 35 or higher, making it a direct test against the current standard rather than placebo alone. No efficacy or safety data have been released.
Key Points
- Three 76-week Phase 3 trials fully enrolled; results due mid-2028
- Dual GLP-1/GIP agonist tested head-to-head against semaglutide 2.4 mg
- Oral ribupatide and triple-receptor candidates advancing behind the injection
Longevity Analysis
Excess adiposity sits upstream of cardiometabolic, inflammatory and structural decline, which places pharmacological weight reduction near the center of current longevity practice. A 76-week endpoint measures weight change, glycemic control and tolerability — not healthspan — so the relevant question is whether deeper weight loss sustained on maintenance dosing translates into preserved metabolic flexibility, vascular function and lean mass over decades. Comparative design against an established agent is more informative than placebo superiority, but the interval between drug-driven loss and durable physiological benefit remains unmeasured, and retention on therapy will likely matter as much as peak efficacy.
Original published by Longevity.Technology, by Kyle Umipig.